메뉴 건너뛰기




Volumn 93, Issue 2, 2014, Pages 293-298

A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation

Author keywords

FLT3; Hematopoietic chimerism; NPM1

Indexed keywords

CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN; NUCLEOPHOSMIN;

EID: 84895064855     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1858-2     Document Type: Article
Times cited : (6)

References (22)
  • 1
    • 0033050404 scopus 로고    scopus 로고
    • Increasing hematopoietic mixed chimerism alter BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse
    • 1:STN:280:DyaK1M7pvVKlsw%3D%3D 10100562 10.1038/sj.bmt.1701604
    • Serrano J, Roman J, Herrera C, Castillejo JA, Reina ML, Gonzalez MG, Rodriguez MC, Pascual A, Sanchez J, Torres A (1999) Increasing hematopoietic mixed chimerism alter BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse. Bone Marrow Transplant 23:475-482
    • (1999) Bone Marrow Transplant , vol.23 , pp. 475-482
    • Serrano, J.1    Roman, J.2    Herrera, C.3    Castillejo, J.A.4    Reina, M.L.5    Gonzalez, M.G.6    Rodriguez, M.C.7    Pascual, A.8    Sanchez, J.9    Torres, A.10
  • 4
    • 0141475940 scopus 로고    scopus 로고
    • Impact or prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation
    • 12766882 10.1016/S1083-8791(03)00077-6
    • Dey BR, McAfee S, Colby C, Sackestein R, Saidman S, Tarbell N, Sachs DH, Sykes M, Spitzer TR (2003) Impact or prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 9(5):320-329
    • (2003) Biol Blood Marrow Transplant , vol.9 , Issue.5 , pp. 320-329
    • Dey, B.R.1    McAfee, S.2    Colby, C.3    Sackestein, R.4    Saidman, S.5    Tarbell, N.6    Sachs, D.H.7    Sykes, M.8    Spitzer, T.R.9
  • 5
    • 18644365146 scopus 로고    scopus 로고
    • Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation
    • 1:CAS:528:DC%2BD2MXjsFOktbc%3D 15772700 10.1038/sj.leu.2403719
    • Zeiser R, Spyridonidis A, Wäsch R, Ihorst G, Grüllich C, Bertz H, Finke J (2005) Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 19:814-821
    • (2005) Leukemia , vol.19 , pp. 814-821
    • Zeiser, R.1    Spyridonidis, A.2    Wäsch, R.3    Ihorst, G.4    Grüllich, C.5    Bertz, H.6    Finke, J.7
  • 6
    • 84881370213 scopus 로고    scopus 로고
    • CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT
    • Feb 4. doi: 10.1038/bmt.2013.2. [Epub ahead of print]
    • Rosenow F, Berkenmeier A, Krug U, Müller-Tidow C, Gerss J, Silling G, Groth C, Wieacker P, Bogdanova N, Mesters R, Büchner T, Kienast J, Berdel WE, Stelljes M. (2013) CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant. 2013 Feb 4. doi: 10.1038/bmt.2013.2. [Epub ahead of print]
    • (2013) Bone Marrow Transplant
    • Rosenow F, B.1
  • 7
    • 0031594385 scopus 로고    scopus 로고
    • Detection of CBFbeta/MYH11 fusion transcripts in patients with inv (16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation
    • 10.1038/sj.bmt.1701056
    • Elmaaglacli AH, Beelen DW, Kroll M, Trzenky S, Stein C, Schaefer UW (1998) Detection of CBFbeta/MYH11 fusion transcripts in patients with inv (16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2:159-166
    • (1998) Bone Marrow Transplant , vol.2 , pp. 159-166
    • Elmaaglacli, A.H.1    Beelen, D.W.2    Kroll, M.3    Trzenky, S.4    Stein, C.5    Schaefer, U.W.6
  • 8
    • 0642368568 scopus 로고    scopus 로고
    • Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias
    • 1:CAS:528:DC%2BD2cXpsVajsrg%3D 14645432 10.1200/JCO.2003.03.166
    • Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G (2003) Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 21(23):4413-4422
    • (2003) J Clin Oncol , vol.21 , Issue.23 , pp. 4413-4422
    • Krauter, J.1    Gorlich, K.2    Ottmann, O.3    Lubbert, M.4    Dohner, H.5    Heit, W.6    Kanz, L.7    Ganser, A.8    Heil, G.9
  • 9
    • 47649090155 scopus 로고    scopus 로고
    • Reduced-toxicity conditioning with fludarabine, BCNU and melphalan in allogeneic hematopoietic cell transplantation: Particular activity against advanced hematologic malignancies
    • 1:CAS:528:DC%2BD1cXos1Cit7c%3D 18451310 10.1182/blood-2007-08-104745
    • Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, Holler E, Finke J (2008) Reduced-toxicity conditioning with fludarabine, BCNU and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 112(2):415-425
    • (2008) Blood , vol.112 , Issue.2 , pp. 415-425
    • Marks, R.1    Potthoff, K.2    Hahn, J.3    Ihorst, G.4    Bertz, H.5    Spyridonidis, A.6    Holler, E.7    Finke, J.8
  • 10
    • 84875417640 scopus 로고    scopus 로고
    • An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation
    • 1:CAS:528:DC%2BC3sXkslSmsr8%3D 23093278 10.1515/cclm-2012-0230
    • Waterhouse M, Kunzmann R, Torres M, Bertz H, Finke J (2013) An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation. Clin Chem Lab Med 51(2):363-369
    • (2013) Clin Chem Lab Med , vol.51 , Issue.2 , pp. 363-369
    • Waterhouse, M.1    Kunzmann, R.2    Torres, M.3    Bertz, H.4    Finke, J.5
  • 11
    • 19044393661 scopus 로고    scopus 로고
    • Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation
    • 15877797 10.1111/j.1399-0012.2005.00347.x
    • Spyridonidis A, Zeiser R, Wäsch R, Bertz H, Finke J (2005) Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation. Clin Transplant 19:350-356
    • (2005) Clin Transplant , vol.19 , pp. 350-356
    • Spyridonidis, A.1    Zeiser, R.2    Wäsch, R.3    Bertz, H.4    Finke, J.5
  • 12
    • 46949098927 scopus 로고    scopus 로고
    • A rapid one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics
    • 1:CAS:528:DC%2BD1cXhtVWqu7vO 18477048 10.1111/j.1365-2141.2008.07205.x
    • Huang Q, Chen W, Gaal K et al (2008) A rapid one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol 142:489-501
    • (2008) Br J Haematol , vol.142 , pp. 489-501
    • Huang, Q.1    Chen, W.2    Gaal, K.3
  • 14
    • 0024580745 scopus 로고
    • Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse
    • 1:STN:280:DyaL1M7psVerug%3D%3D 2564791
    • Schattenberg A, De Witte T, Salden M, Vet J, Van Dijk B, Smeets D, Hoogenhout J, Haanen C (1989) Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. Blood 73(5):1367-1372
    • (1989) Blood , vol.73 , Issue.5 , pp. 1367-1372
    • Schattenberg, A.1    De Witte, T.2    Salden, M.3    Vet, J.4    Van Dijk, B.5    Smeets, D.6    Hoogenhout, J.7    Haanen, C.8
  • 15
    • 0027227876 scopus 로고
    • Mixed T lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse
    • 8400242
    • van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Khan PM, Vossen JM (1993) Mixed T lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse. Blood 82(6):1921-1928
    • (1993) Blood , vol.82 , Issue.6 , pp. 1921-1928
    • Van Leeuwen, J.E.1    Van Tol, M.J.2    Joosten, A.M.3    Wijnen, J.T.4    Khan, P.M.5    Vossen, J.M.6
  • 16
    • 0028905531 scopus 로고
    • Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance
    • 1:CAS:528:DyaK2MXktlOgtLw%3D 7888664
    • Campana D, Pui CH (1995) Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 85(6):1416-1434
    • (1995) Blood , vol.85 , Issue.6 , pp. 1416-1434
    • Campana, D.1    Pui, C.H.2
  • 17
    • 0038268132 scopus 로고    scopus 로고
    • Determination of minimal residual disease in leukemia patients
    • 12786792 10.1046/j.1365-2141.2003.04393.x
    • Campana D (2003) Determination of minimal residual disease in leukemia patients. Br J Haematol 121(6):823-838
    • (2003) Br J Haematol , vol.121 , Issue.6 , pp. 823-838
    • Campana, D.1
  • 18
    • 0036659931 scopus 로고    scopus 로고
    • Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
    • 1:CAS:528:DC%2BD38XltF2rs7g%3D 12070009 10.1182/blood.V100.1.59
    • Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland CM, Serve H, Büchner T, Haferlach T, Hiddemann W (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100(1):59-66
    • (2002) Blood , vol.100 , Issue.1 , pp. 59-66
    • Schnittger, S.1    Schoch, C.2    Dugas, M.3    Kern, W.4    Staib, P.5    Wuchter, C.6    Löffler, H.7    Sauerland, C.M.8    Serve, H.9    Büchner, T.10    Haferlach, T.11    Hiddemann, W.12
  • 19
    • 70349579540 scopus 로고    scopus 로고
    • Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
    • 1:CAS:528:DC%2BD1MXhtFOgtrbF 19587375 10.1182/blood-2009-03-213389
    • Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114(11):2220-2231
    • (2009) Blood , vol.114 , Issue.11 , pp. 2220-2231
    • Schnittger, S.1    Kern, W.2    Tschulik, C.3    Weiss, T.4    Dicker, F.5    Falini, B.6    Haferlach, C.7    Haferlach, T.8
  • 21
    • 58649090874 scopus 로고    scopus 로고
    • Monitoring minimal residual disease in acute myeloid leukemia with NPM1 mutations by quantitative PCR: Clonal evolution is a limiting factor
    • 1:CAS:528:DC%2BD1MXjtlehtrw%3D 19055671 10.1111/j.1365-2141.2008.07488.x
    • Papadaki C, Dufuor A, Seibl M, Schneider S, Bohlander SK, Zellmeier E, Mellert G, Hiddemann W, Spiekermann K (2009) Monitoring minimal residual disease in acute myeloid leukemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 144(4):517-523
    • (2009) Br J Haematol , vol.144 , Issue.4 , pp. 517-523
    • Papadaki, C.1    Dufuor, A.2    Seibl, M.3    Schneider, S.4    Bohlander, S.K.5    Zellmeier, E.6    Mellert, G.7    Hiddemann, W.8    Spiekermann, K.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.